Aztiq Announces Secondary Sale of a Portion of its Holding in Lotus Pharmaceutical Company

Aztiq Lotus Sarl (“Aztiq”), an investment company focused on the life sciences sector, (“the shareholder”), today announced the sale of 3,000,000 shares of Lotus Pharmaceutical Company (1795:TT; “Lotus”, “the Company”), a multinational pharmaceutical company at market price.

The sale represents a limited proportion of Aztiq’s overall holding in Lotus and reflects a partial monetisation of its position. Following completion, Aztiq will hold 23,521,723 shares, representing 8.8% of the Company’s outstanding share capital.

The sale is expected to further broaden the Company’s institutional shareholder base and forms part of Aztiq’s ongoing portfolio and balance sheet management, providing additional liquidity for general corporate purposes. It reflects active portfolio management while maintaining Aztiq’s strong commitment to Lotus as a long-term shareholder. Aztiq continues to have high conviction in the company’s long-term strategy and growth trajectory.